• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

无症状 COVID-19 感染中上调的 I 型干扰素反应与改善的临床结局相关。

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome.

机构信息

Department of Pathology and Laboratory Medicine, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi, 75400, Pakistan.

Department of Medicine, AKU, Karachi, Pakistan.

出版信息

Sci Rep. 2021 Nov 25;11(1):22958. doi: 10.1038/s41598-021-02489-4.

DOI:10.1038/s41598-021-02489-4
PMID:34824360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8617268/
Abstract

Understanding key host protective mechanisms against SARS-CoV-2 infection can help improve treatment modalities for COVID-19. We used a blood transcriptome approach to study biomarkers associated with differing severity of COVID-19, comparing severe and mild Symptomatic disease with Asymptomatic COVID-19 and uninfected Controls. There was suppression of antigen presentation but upregulation of inflammatory and viral mRNA translation associated pathways in Symptomatic as compared with Asymptomatic cases. In severe COVID-19, CD177 a neutrophil marker, was upregulated while interferon stimulated genes (ISGs) were downregulated. Asymptomatic COVID-19 cases displayed upregulation of ISGs and humoral response genes with downregulation of ICAM3 and TLR8. Compared across the COVID-19 disease spectrum, we found type I interferon (IFN) responses to be significantly upregulated (IFNAR2, IRF2BP1, IRF4, MAVS, SAMHD1, TRIM1), or downregulated (SOCS3, IRF2BP2, IRF2BPL) in Asymptomatic as compared with mild and severe COVID-19, with the dysregulation of an increasing number of ISGs associated with progressive disease. These data suggest that initial early responses against SARS-CoV-2 may be effectively controlled by ISGs. Therefore, we hypothesize that treatment with type I interferons in the early stage of COVID-19 may limit disease progression by limiting SARS-CoV-2 in the host.

摘要

了解宿主针对 SARS-CoV-2 感染的关键保护机制有助于改进 COVID-19 的治疗方法。我们采用血液转录组学方法研究与 COVID-19 严重程度相关的生物标志物，将重症和轻症有症状疾病与无症状 COVID-19 和未感染对照进行比较。与无症状病例相比，有症状病例中抗原呈递受到抑制，但炎症和病毒 mRNA 翻译相关途径上调。在重症 COVID-19 中，中性粒细胞标志物 CD177 上调，而干扰素刺激基因 (ISG) 下调。无症状 COVID-19 病例中 ISG 和体液反应基因上调，ICAM3 和 TLR8 下调。与 COVID-19 疾病谱相比，我们发现与轻症和重症 COVID-19 相比，I 型干扰素 (IFN) 反应在无症状病例中显著上调 (IFNAR2、IRF2BP1、IRF4、MAVS、SAMHD1、TRIM1) 或下调 (SOCS3、IRF2BP2、IRF2BPL)，与疾病进展相关的 ISG 失调数量增加。这些数据表明，针对 SARS-CoV-2 的初始早期反应可能被 ISG 有效控制。因此，我们假设在 COVID-19 的早期阶段使用 I 型干扰素治疗可能通过限制宿主中的 SARS-CoV-2 来限制疾病进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/27e95cd0e959/41598_2021_2489_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/d71ef3ce478b/41598_2021_2489_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/d1f940e466ee/41598_2021_2489_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/0e0396688638/41598_2021_2489_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/7809a00e94f1/41598_2021_2489_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/4e0c1bb034f4/41598_2021_2489_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/27e95cd0e959/41598_2021_2489_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/d71ef3ce478b/41598_2021_2489_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/d1f940e466ee/41598_2021_2489_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/0e0396688638/41598_2021_2489_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/7809a00e94f1/41598_2021_2489_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/4e0c1bb034f4/41598_2021_2489_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b4cb/8617268/27e95cd0e959/41598_2021_2489_Fig6_HTML.jpg

相似文献

1
Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome.无症状 COVID-19 感染中上调的 I 型干扰素反应与改善的临床结局相关。
Sci Rep. 2021 Nov 25;11(1):22958. doi: 10.1038/s41598-021-02489-4.
2
Differentially expressed immune response genes in COVID-19 patients based on disease severity.基于疾病严重程度的 COVID-19 患者差异表达免疫反应基因。
Aging (Albany NY). 2021 Mar 29;13(7):9265-9276. doi: 10.18632/aging.202877.
3
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection.无症状和重症 COVID-19 感染中的浆细胞样树突状细胞表型和 I 型干扰素反应的差异。
PLoS Pathog. 2021 Sep 2;17(9):e1009878. doi: 10.1371/journal.ppat.1009878. eCollection 2021 Sep.
4
Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients.单细胞免疫谱分析揭示无症状 COVID-19 患者的独特免疫反应。
Signal Transduct Target Ther. 2021 Sep 16;6(1):342. doi: 10.1038/s41392-021-00753-7.
5
Dysregulated early transcriptional signatures linked to mast cell and interferon responses are implicated in COVID-19 severity.失调的早期转录特征与肥大细胞和干扰素反应有关，这些特征与 COVID-19 的严重程度有关。
Front Immunol. 2023 May 16;14:1166574. doi: 10.3389/fimmu.2023.1166574. eCollection 2023.
6
Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.通过I/III型干扰素的时间模式及流感对比揭示的新冠病毒感染中失调的抗病毒免疫
Nat Immunol. 2021 Jan;22(1):32-40. doi: 10.1038/s41590-020-00840-x. Epub 2020 Dec 4.
7
Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients.基于数据驱动的 SARS-CoV-2 感染多尺度数学建模揭示了 COVID-19 患者之间的异质性。
PLoS Comput Biol. 2021 Nov 24;17(11):e1009587. doi: 10.1371/journal.pcbi.1009587. eCollection 2021 Nov.
8
SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors.SARS-CoV-2 非结构蛋白 1 通过导致关键宿主信号因子耗竭来抑制干扰素反应。
J Virol. 2021 Jun 10;95(13):e0026621. doi: 10.1128/JVI.00266-21.
9
Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19.炎症和抗病毒免疫反应与 COVID-19 的严重进展相关。
Front Immunol. 2021 Feb 18;12:631226. doi: 10.3389/fimmu.2021.631226. eCollection 2021.
10
Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19.社论：针对免疫系统成分（包括 1 型干扰素）的自身抗体与 COVID-19 重症风险。
Med Sci Monit. 2021 Sep 20;27:e934766. doi: 10.12659/MSM.934766.

引用本文的文献

1
CD39 dynamics in tuberculosis: a potential biomarker of immune dysregulation and T cell exhaustion.结核病中CD39的动态变化：免疫失调和T细胞耗竭的潜在生物标志物。
Front Immunol. 2025 Aug 11;16:1601637. doi: 10.3389/fimmu.2025.1601637. eCollection 2025.
2
GIGYF2: A Multifunctional Regulator at the Crossroads of Gene Expression, mRNA Surveillance, and Human Disease.GIGYF2：基因表达、mRNA监测与人类疾病交叉路口的多功能调节因子
Cells. 2025 Jul 5;14(13):1032. doi: 10.3390/cells14131032.
3
Different Expression of Nuclear Respiratory Factor 1 (NRF-1) Gene in COVID-19: An Insight into Disease Severity.

本文引用的文献

1
Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19.早期 IFN-α 特征和持续功能障碍是严重 COVID-19 中 NK 细胞的显著特征。
Immunity. 2021 Nov 9;54(11):2650-2669.e14. doi: 10.1016/j.immuni.2021.09.002. Epub 2021 Sep 4.
2
The biological and clinical significance of emerging SARS-CoV-2 variants.新兴 SARS-CoV-2 变体的生物学和临床意义。
Nat Rev Genet. 2021 Dec;22(12):757-773. doi: 10.1038/s41576-021-00408-x. Epub 2021 Sep 17.
3
Higher entropy observed in SARS-CoV-2 genomes from the first COVID-19 wave in Pakistan.
核呼吸因子1（NRF-1）基因在新型冠状病毒肺炎中的不同表达：对疾病严重程度的深入了解
Curr Microbiol. 2025 May 30;82(7):317. doi: 10.1007/s00284-025-04296-w.
4
BCR, not TCR, repertoire diversity is associated with favorable COVID-19 prognosis.BCR 而非 TCR 受体库多样性与 COVID-19 预后良好相关。
Front Immunol. 2024 Oct 28;15:1405013. doi: 10.3389/fimmu.2024.1405013. eCollection 2024.
5
Longitudinal transcriptional changes reveal genes from the natural killer cell-mediated cytotoxicity pathway as critical players underlying COVID-19 progression.纵向转录变化揭示了自然杀伤细胞介导的细胞毒性通路中的基因，这些基因是 COVID-19 进展的关键因素。
Elife. 2024 Oct 29;13:RP94242. doi: 10.7554/eLife.94242.
6
SARS-CoV-2 variants induce increased inflammatory gene expression but reduced interferon responses and heme synthesis as compared with wild type strains.与野生型毒株相比，SARS-CoV-2 变异株诱导炎症基因表达增加，但干扰素反应和血红素合成减少。
Sci Rep. 2024 Oct 28;14(1):25734. doi: 10.1038/s41598-024-76401-1.
7
Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC).揭示新冠后综合征（PASC）中的差异与联系：急性新冠肺炎与新冠病毒2型（SARS-CoV-2）急性后遗症中的病毒载量和细胞因子特征
Biomedicines. 2024 Aug 23;12(9):1941. doi: 10.3390/biomedicines12091941.
8
An human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy.一种人类精确切割肺切片平台提供了对 SARS-CoV-2 发病机制和抗病毒药物疗效的深入了解。
J Virol. 2024 Jul 23;98(7):e0079424. doi: 10.1128/jvi.00794-24. Epub 2024 Jun 28.
9
Whole blood transcriptome signature predicts severe forms of COVID-19: Results from the COVIDeF cohort study.全血转录组特征可预测 COVID-19 的严重形式：COVIDeF 队列研究结果。
Funct Integr Genomics. 2024 May 21;24(3):107. doi: 10.1007/s10142-024-01359-2.
10
SARS-CoV-2 Omicron BA.1 Variant Infection of Human Colon Epithelial Cells.严重急性呼吸综合征冠状病毒2型奥密克戎BA.1变异株对人结肠上皮细胞的感染
Viruses. 2024 Apr 19;16(4):634. doi: 10.3390/v16040634.
在巴基斯坦首次 COVID-19 浪潮中观察到的 SARS-CoV-2 基因组中存在更高的熵。
PLoS One. 2021 Aug 31;16(8):e0256451. doi: 10.1371/journal.pone.0256451. eCollection 2021.
4
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?干扰 SARS-CoV-2：干扰素在 COVID-19 中是敌是友？
Curr Opin Virol. 2021 Oct;50:119-127. doi: 10.1016/j.coviro.2021.08.004. Epub 2021 Aug 17.
5
SAMD9L autoinflammatory or ataxia pancytopenia disease mutations activate cell-autonomous translational repression.SAMD9L 自身炎症或小脑共济失调全血细胞减少症突变激活细胞自主翻译抑制。
Proc Natl Acad Sci U S A. 2021 Aug 24;118(34). doi: 10.1073/pnas.2110190118.
6
COVID-19 situation in Pakistan: A broad overview.巴基斯坦的新冠疫情：概述
Respirology. 2021 Sep;26(9):891-892. doi: 10.1111/resp.14093. Epub 2021 May 31.
7
Clinical characteristics and outcomes of COVID-19: Experience at a major tertiary care center in Pakistan.新型冠状病毒肺炎的临床特征和结局：巴基斯坦一家主要三级护理中心的经验。
J Infect Dev Ctries. 2021 Apr 30;15(4):480-489. doi: 10.3855/jidc.14345.
8
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.干扰素治疗在重症 COVID-19 中的作用：COVIFERON 随机对照试验。
Sci Rep. 2021 Apr 13;11(1):8059. doi: 10.1038/s41598-021-86859-y.
9
Lung Protection vs. Infection Resolution: Interleukin 10 Suspected of Double-Dealing in COVID-19.肺保护与感染清除：白细胞介素 10 被怀疑在 COVID-19 中两面三刀。
Front Immunol. 2021 Mar 3;12:602130. doi: 10.3389/fimmu.2021.602130. eCollection 2021.
10
Serial population-based serosurveys for COVID-19 in two neighbourhoods of Karachi, Pakistan.巴基斯坦卡拉奇两个街区的基于人群的 COVID-19 连续血清学调查。
Int J Infect Dis. 2021 May;106:176-182. doi: 10.1016/j.ijid.2021.03.040. Epub 2021 Mar 15.